Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

Novo Nordisk A/S339 enrolled

Overview

This study is conducted in Asia. The aim of this observational study is to evaluate the safety profile and clinical effectiveness of using various pre-mixes of Biphasic Insulin Aspart under routine clinical practice conditions in Israel in Type 2 Diabetes patients.

Study Type

OBSERVATIONAL

Enrollment

339

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

biphasic insulin aspart 50DRUG

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

biphasic insulin aspart 70DRUG

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Any patient with type 2 diabetes who has HbA1c greater than 7% on insulin with or without OAD and who needs intensification of treatment with either NovoMix® 30 or NovoMix® 50 or NovoMix® 70 or combinations, will be eligible Exclusion Criteria: * Subjects with a hypersensitivity to biphasic insulin aspart or to any of the excipients. Particular attention should be paid to the drug interactions that are listed within the product local label. * Women who are pregnant, breast feeding or have the intention of becoming pregnant within the next 12 months.

Locations (1)

Novo Nordisk Investigational Site

Kfar Saba, Israel